Spero was founded to address the serious infections and the growing global threat of antibiotic resistance through innovative therapeutic approaches. Our ability to provide effective therapies today will have long-term impacts on patients’ lives.
We’ve built an organization on foundations of stability, momentum and commitment to excellence. Spero’s future hinges on the success + proper stewardship of our current arsenal, as well as shaping the conversation to educate the public on the ability of these drugs to keep people out of the hospital.
Spero Therapeutics is committed to advancing novel treatment approaches for bacterial infections. Our world-class team of biotechnology and biopharmaceutical experts embraces the Italian word “spero” which means “hope.” It is our mission to bring hope to patients and families of loved ones suffering from serious infections.
Led by an executive team with deep experience and world-class scientific talent, Spero is dedicated to delivering differentiated medicines that help patients suffering from serious and life-threatening infections.
Founded in 2013, and named as one Boston’s Best Places to Work in 2021, 2020 and 2017 by the Boston Business Journal, Spero Therapeutics is also the recipient of the first-ever 2017 Xconomy Startup of the Year Award.
Spero Therapeutics is actively pursuing collaborations with partners for scientific expertise and funding support.
Stock information, SEC filings, corporate governance, IR resources and more.
Collaborative. Exciting. Challenging. Stimulating. Committed.